-->

Ramm Pharma Corp Stock Net Asset

Fundamental analysis of RAMM Pharma allows traders to better anticipate movements in RAMM Pharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

RAMM Pharma Corp Company Net Asset Analysis

RAMM Pharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Net Asset

 = 

Current Market Value

-

Current Liabilities

More About Net Asset | All Equity Analysis

Current RAMM Pharma Net Asset

    
  59.71 M  
Most of RAMM Pharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RAMM Pharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition

Based on the recorded statements, RAMM Pharma Corp has a Net Asset of 59.71 M. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net asset for all United States stocks is notably lower than that of the firm.

RAMM Net Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RAMM Pharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of RAMM Pharma could also be used in its relative valuation, which is a method of valuing RAMM Pharma by comparing valuation metrics of similar companies.
RAMM Pharma is currently under evaluation in net asset category among its peers.

RAMM Fundamentals

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Consideration for investing in RAMM Pink Sheet

If you are still planning to invest in RAMM Pharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RAMM Pharma's history and understand the potential risks before investing.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume